HRP20221277T1 - Kondenzirani heterociklični spoj - Google Patents
Kondenzirani heterociklični spoj Download PDFInfo
- Publication number
- HRP20221277T1 HRP20221277T1 HRP20221277TT HRP20221277T HRP20221277T1 HR P20221277 T1 HRP20221277 T1 HR P20221277T1 HR P20221277T T HRP20221277T T HR P20221277TT HR P20221277 T HRP20221277 T HR P20221277T HR P20221277 T1 HRP20221277 T1 HR P20221277T1
- Authority
- HR
- Croatia
- Prior art keywords
- hydrate
- methyl
- salt
- compound
- methoxypyrrolo
- Prior art date
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 3
- 125000003277 amino group Chemical group 0.000 claims 2
- -1 color Substances 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000000069 prophylactic effect Effects 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- BGVLELSCIHASRV-UHFFFAOYSA-N 1-(3-ethyl-5-methoxy-1,3-benzothiazol-2-ylidene)propan-2-one Chemical compound C1=C(OC)C=C2N(CC)C(=CC(C)=O)SC2=C1 BGVLELSCIHASRV-UHFFFAOYSA-N 0.000 claims 1
- IDOHQTGVUODMJH-UHFFFAOYSA-N 2-(1,1-difluoroethyl)-5-[[6-(4-methoxypyrrolo[2,1-f][1,2,4]triazin-5-yl)-2-methylimidazo[4,5-b]pyridin-1-yl]methyl]-1,3,4-oxadiazole Chemical compound FC(C)(F)C1=NN=C(O1)CN1C(=NC2=NC=C(C=C21)C=1C=CN2N=CN=C(C2=1)OC)C IDOHQTGVUODMJH-UHFFFAOYSA-N 0.000 claims 1
- YAPFGKINYKSSHP-UHFFFAOYSA-N 2-(difluoromethyl)-5-[[6-(4-methoxypyrrolo[2,1-f][1,2,4]triazin-5-yl)-2-methylimidazo[4,5-b]pyridin-1-yl]methyl]-1,3,4-oxadiazole Chemical compound FC(C1=NN=C(O1)CN1C(=NC2=NC=C(C=C21)C=1C=CN2N=CN=C(C2=1)OC)C)F YAPFGKINYKSSHP-UHFFFAOYSA-N 0.000 claims 1
- OENNTZBJPRRGFL-SNVBAGLBSA-N 2-[(1R)-1-fluoroethyl]-5-[[6-(4-methoxypyrrolo[2,1-f][1,2,4]triazin-5-yl)-2-methylimidazo[4,5-b]pyridin-1-yl]methyl]-1,3,4-oxadiazole Chemical compound F[C@H](C)C1=NN=C(O1)CN1C(=NC2=NC=C(C=C21)C=1C=CN2N=CN=C(C2=1)OC)C OENNTZBJPRRGFL-SNVBAGLBSA-N 0.000 claims 1
- LYGXZVFGVDVDFR-UHFFFAOYSA-N 5-[[6-(4-methoxypyrrolo[2,1-f][1,2,4]triazin-5-yl)-2-methylimidazo[4,5-b]pyridin-1-yl]methyl]-3-methyl-1,2,4-thiadiazole Chemical compound COC1=NC=NN2C1=C(C=C2)C=1C=C2C(=NC=1)N=C(N2CC1=NC(=NS1)C)C LYGXZVFGVDVDFR-UHFFFAOYSA-N 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 239000007884 disintegrant Substances 0.000 claims 1
- 239000003995 emulsifying agent Substances 0.000 claims 1
- 235000003599 food sweetener Nutrition 0.000 claims 1
- 239000003205 fragrance Substances 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 239000000375 suspending agent Substances 0.000 claims 1
- 239000003765 sweetening agent Substances 0.000 claims 1
- 239000004034 viscosity adjusting agent Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Claims (10)
1. Spoj predstavljen formulom (I), ili njegova sol ili hidrat:
[image]
u kojem
R1 predstavlja C1-6 alkil grupu koja izborno ima 1 do 3 hidroksi grupe,
R2 predstavlja C1-6 alkil grupu koja ima 1 do 3 peto- ili šestočlane monociklične aromatične heterociklične grupe koje izborno imaju 1 do 3 izborno halogenirane C1-6 alkil grupe,
R6 i R7 svaki predstavlja atom vodika, i pri čemu
prsten A je biciklični aromatični heterociklus predstavljen sljedećom formulom (1)
[image]
u kojem
R3 je atom vodika;
R4 je (a) amino grupa,
(a') amino grupa monosupstituirana ili disupstituirana sa C1-6 alkil grupom, ili
(b) C1-6 alkoksi grupa, i
X je N.
2. Spoj prema zahtjevu 1, koje je 6-(4-metoksipirolo[2,1-f][1,2,4]triazin-5-il)-2-metil-1-((3-metil-1,2,4-tiadiazol-5-il)metil)-1H-imidazo[4,5-b]piridin, ili njegova sol ili hidrat.
3. Spoj prema zahtjevu 1, koje je 1-((5-(difluorometil)-1,3,4-oksadiazol-2-il)metil)-6-(4-metoksipirolo[2,1-f][1,2,4]triazin-5-il)-2-metil-1H-imidazo[4,5-b]piridin, ili njegova sol ili hidrat.
4. Spoj prema zahtjevu 1, koje je 1-((5-(1,1-difluoroetil)-1,3,4-oksadiazol-2-il)metil)-6-(4-metoksipirolo[2,1-f][1,2,4]triazin-5-il)-2-metil-1H-imidazo[4,5-b]piridin, ili njegova sol ili hidrat.
5. Spoj prema zahtjevu 1, koje je 1-((5-((1R)-1-fluoroetil)-1,3,4-oksadiazol-2-il)metil)-6-(4-metoksipirolo[2,1-f][1,2,4]triazin-5-il)-2-metil-1H-imidazo[4,5-b]piridin, ili njegova sol ili hidrat.
6. Lijek koji sadrži spoj, ili njegovu sol ili hidrat prema bilo kojem od zahtjeva 1 do 5.
7. Lijek prema zahtjevu 6 koji je inhibitor CLK za uporabu u prevenciji i liječenju raka.
8. Lijek prema zahtjevu 6 za uporabu kao profilaktičko ili terapeutsko sredstvo u prevenciji ili liječenju raka.
9. Spoj, ili njegova sol ili hidrat prema bilo kojem od zahtjeva 1 do 5 za uporabu u prevenciji i liječenju raka.
10. Uporaba spoja, ili njegove soli ili hidrata prema zahtjevu 1 u proizvodnji profilaktičkog ili terapeutskog sredstva za uporabu u prevenciji ili liječenju raka, pri čemu proizvodnja sadrži korak kombiniranja spojeva, ili njegovog hidrata ili soli prema bilo kojem od patentnih zahtjeva 1 do 5 sa aditivom kao što je ekscipijens, vezujuće sredstvo, sredstvo za raspadanje, lubrikant, zaslađivač, surfaktant, suspendirajuće sredstvo, emulgator, boja, konzervans, miris, korigens, stabilizator ili modifikator viskoziteta.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016091717 | 2016-04-28 | ||
| EP17789656.0A EP3450436B1 (en) | 2016-04-28 | 2017-04-27 | Condensed heterocyclic compound |
| PCT/JP2017/016717 WO2017188374A1 (ja) | 2016-04-28 | 2017-04-27 | 縮合複素環化合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20221277T1 true HRP20221277T1 (hr) | 2022-12-23 |
Family
ID=60159711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20221277TT HRP20221277T1 (hr) | 2016-04-28 | 2017-04-27 | Kondenzirani heterociklični spoj |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US10577382B2 (hr) |
| EP (1) | EP3450436B1 (hr) |
| JP (2) | JP6924182B2 (hr) |
| KR (1) | KR102431405B1 (hr) |
| CN (1) | CN109415384B (hr) |
| BR (1) | BR112018072039B1 (hr) |
| CA (1) | CA3021185A1 (hr) |
| DK (1) | DK3450436T3 (hr) |
| EA (1) | EA039529B1 (hr) |
| ES (1) | ES2927529T3 (hr) |
| HR (1) | HRP20221277T1 (hr) |
| HU (1) | HUE059954T2 (hr) |
| LT (1) | LT3450436T (hr) |
| MA (1) | MA44781B1 (hr) |
| PL (1) | PL3450436T3 (hr) |
| PT (1) | PT3450436T (hr) |
| RS (1) | RS63656B1 (hr) |
| SG (2) | SG11201809243YA (hr) |
| WO (1) | WO2017188374A1 (hr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3450436T3 (da) | 2016-04-28 | 2022-09-12 | Takeda Pharmaceuticals Co | Kondenseret heterocyklisk forbindelse |
| CN113773247A (zh) * | 2021-07-23 | 2021-12-10 | 无锡海伦生物科技有限公司 | 一种2-氨基-5-碘吡啶的制备方法 |
| WO2023190967A1 (ja) * | 2022-03-31 | 2023-10-05 | Ｃｈｏｒｄｉａ Ｔｈｅｒａｐｅｕｔｉｃｓ株式会社 | イミダゾ［４，５－ｂ］ピリジン誘導体による固形癌治療のためのバイオマーカー |
| CN115006411A (zh) * | 2022-07-26 | 2022-09-06 | 中南大学湘雅医院 | 依拉环素类化合物的应用、药物及其制备方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6982265B1 (en) | 1999-05-21 | 2006-01-03 | Bristol Myers Squibb Company | Pyrrolotriazine inhibitors of kinases |
| DE60026297T2 (de) | 1999-05-21 | 2006-11-02 | Bristol-Myers Squibb Co. | Pyrrolotriazin kinasehemmer |
| TWI329112B (en) | 2002-07-19 | 2010-08-21 | Bristol Myers Squibb Co | Novel inhibitors of kinases |
| EP2308877B1 (en) * | 2008-08-05 | 2014-01-22 | Daiichi Sankyo Company, Limited | Imidazopyridin-2-one derivatives |
| EP2987487B1 (en) * | 2009-08-10 | 2020-10-07 | Samumed, LLC | Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof |
| EP2464231A4 (en) * | 2009-08-10 | 2013-02-06 | Samumed Llc | INDAZOLE AS WNT / B-CATENINE SIGNALING PATHWASHER AND THERAPEUTIC APPLICATIONS THEREOF |
| WO2012003576A1 (en) * | 2010-07-06 | 2012-01-12 | Université de Montréal | Imidazopyridine, imidazopyrimidine and imidazopyrazine derivatives as melanocortin-4 receptor modulators |
| US9050345B2 (en) | 2013-03-11 | 2015-06-09 | Bristol-Myers Squibb Company | Pyrrolotriazines as potassium ion channel inhibitors |
| DK3450436T3 (da) * | 2016-04-28 | 2022-09-12 | Takeda Pharmaceuticals Co | Kondenseret heterocyklisk forbindelse |
-
2017
- 2017-04-27 DK DK17789656.0T patent/DK3450436T3/da active
- 2017-04-27 EP EP17789656.0A patent/EP3450436B1/en active Active
- 2017-04-27 EA EA201892449A patent/EA039529B1/ru unknown
- 2017-04-27 PL PL17789656.0T patent/PL3450436T3/pl unknown
- 2017-04-27 CA CA3021185A patent/CA3021185A1/en active Granted
- 2017-04-27 HU HUE17789656A patent/HUE059954T2/hu unknown
- 2017-04-27 HR HRP20221277TT patent/HRP20221277T1/hr unknown
- 2017-04-27 PT PT177896560T patent/PT3450436T/pt unknown
- 2017-04-27 MA MA44781A patent/MA44781B1/fr unknown
- 2017-04-27 WO PCT/JP2017/016717 patent/WO2017188374A1/ja active Application Filing
- 2017-04-27 JP JP2018514698A patent/JP6924182B2/ja active Active
- 2017-04-27 KR KR1020187033807A patent/KR102431405B1/ko active IP Right Grant
- 2017-04-27 SG SG11201809243YA patent/SG11201809243YA/en unknown
- 2017-04-27 CN CN201780040291.9A patent/CN109415384B/zh active Active
- 2017-04-27 US US16/094,030 patent/US10577382B2/en active Active
- 2017-04-27 ES ES17789656T patent/ES2927529T3/es active Active
- 2017-04-27 LT LTEPPCT/JP2017/016717T patent/LT3450436T/lt unknown
- 2017-04-27 SG SG10201912270PA patent/SG10201912270PA/en unknown
- 2017-04-27 BR BR112018072039-9A patent/BR112018072039B1/pt active IP Right Grant
- 2017-04-27 RS RS20220958A patent/RS63656B1/sr unknown
-
2019
- 2019-10-25 US US16/663,601 patent/US10981934B2/en active Active
-
2020
- 2020-12-22 US US17/130,297 patent/US11390634B2/en active Active
-
2021
- 2021-07-30 JP JP2021125250A patent/JP7130098B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20221277T1 (hr) | Kondenzirani heterociklični spoj | |
| PH12014502886A1 (en) | NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-d]PYRIMIDINES AS LRRK2 INHIBITORS | |
| MX2018003215A (es) | Derivados de imidazo[4,5-c]quinolina e imidazo[4,5-c][1,5]naftirid ina novedosos como inhibidores de lrrk2. | |
| HRP20200274T1 (hr) | Terapeutski aktivni spojevi i postupci njihove uporabe | |
| CA2864222A1 (en) | Cycloalkane derivative | |
| MX2016015544A (es) | Nuevos derivados de pirazolo pirimidina y su uso como inhibidores de malt1. | |
| AR109295A1 (es) | Compuestos tricíclicos que contienen nitrógeno y usos de los mismos en medicina | |
| MY194405A (en) | Dihydropyrimidine compounds and uses thereof in medicine | |
| PE20170127A1 (es) | Indazol-3-carboxamidas 5-sustituidas y preparacion y uso de las mismas | |
| RU2013149174A (ru) | Новое имидазооксазиновое соединение или его соль | |
| HRP20181036T1 (hr) | 2,6-supstituirani derivati purina i njihova upotreba u liječenju proliferativnih poremećaja | |
| UY31193A1 (es) | Derivados de 6-cicloamino-3-(piridin-4-il)imidazo[1,2-b]-piridazina, su preparasción y su aplicación en terapéutica | |
| JP2015520769A5 (hr) | ||
| UA99617C2 (ru) | Производные пирролконденсированного азотсодержащего гетероцикла, их получение и фармацевтическое применение | |
| MY196172A (en) | Tricyclic Spiro Compound | |
| MX344276B (es) | Compuesto de piperidina novedoso o sal del mismo. | |
| DK2868660T3 (da) | Anti-tumoreffekt-potentiator omfattende en imidazooxazin-forbindelse | |
| PH12019500839A1 (en) | Therapeutic compounds and methods of use thereof | |
| SA519402103B1 (ar) | 1,6-naphthyridine مشتقات 1، 6 نفثيرايدين CDK4/6 على شكل مثبط | |
| PH12017502254B1 (en) | Pyrazole derivative or pharmaceutically acceptable salt thereof | |
| ECSP099767A (es) | Derivados de n' - (fenil) -n- (morfolin-4-il-piridin-2-il) -pirimidina-2, 4-diamina como inhibidores de quinasas ephb4 para el tratamiento de afecciones proliferativas | |
| MX2018002738A (es) | Derivados de piridin-2-ona fusionados triciclicos, y su uso como inhibidores de brd4. | |
| MX367913B (es) | Derivados de 4,5,6,7-tetrahidro-pirazolo[1,5-a]pirimidina y 2,3-dihidro-1h-imidazo[1,2-b]pirazol sustituidos como inhibidores de ros1. | |
| TW200602344A (en) | Novel pyrrolo(2, 3-b)pyridine derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors | |
| MX2019010756A (es) | Derivados novedosos de imidazo[4,5-c]quinolina como inhibidores de cinasa 2 rica en repetición de leucina (lrrk2). |